Inflamax introduces ePDAT for real-time PRO data collection

Article

New tablet facilitates and standardizes patient reported outcomes data collection.

Toronto, Ontario-Inflamax Research has introduced its electronic Patient Data Acquisition Tablet (ePDAT) which not only facilitates but standardizes patient reported outcomes (PRO) data collection across multi-center clinical trials.

The validated ePDAT system provides a graphical user interface via a touchscreen tablet computer designed to provide an improved user experience. The system was designed to enhance user experience, accuracy, and quality while ensuring compliance with FDA and EMA requirements for validated ePRO data collection tools. ePDAT is fully CFR21 part 11 compliant.

PRO data can be collected by on-screen questionnaires, visual analog scales (VAS), response time, coordination tasks, high-resolution image capture, and evaluator interview via video conferencing.

Software architecture allows patient data to be recorded in real-time via the tablet’s cellular wireless connection to the company’s secure database servers. Data is also stored locally on the tablet as backup. 

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Setting the stage in LA: Neda Shamie, MD, on the 19th annual Controversies in Modern Eye Care meeting
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
© 2025 MJH Life Sciences

All rights reserved.